β cell replacement for the treatment of diabetes

Annals of the New York Academy of Sciences

Volumn 944, Issue , 2001, Pages 373-387

  Oberholzer, José ^a   Toso, Christian ^a   Ris, Frédéric ^a   Bucher, Pascal ^a   Triponez, Frédéric ^a   Alp, Demirag ^a   Lou, Jinning ^a   Morel, Philippe ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bioartificial pancreas; Diabetes; Islet isolation; Islet transplantation; cell

Indexed keywords

C PEPTIDE; CYCLOSPORIN; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID; STEROID;

ARTIFICIAL PANCREAS; BIOARTIFICIAL ORGAN; CELL TRANSFER; CONFERENCE PAPER; DIABETES MELLITUS; DIABETOGENESIS; FUTUROLOGY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; TISSUE SECTION;

EID: 0035687778     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03849.x     Document Type: Conference Paper

References (80)

1. Notes on diabetes treated with grafts of sheep's pancreas
2. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
3. Method for the isolation of intact islets of Langerhans from the rat pancreas
4. Transplantation of intact pancreatic islets in rats
5. Successful intrasplenic autotransplantation of pancreatic tissue in totally pancreatectomised dogs
6. Transplantation of isolated islets of Langerhans into the liver of diabetic dogs
7. Human islet transplantation: A preliminary report
8. Transplantation of dispersed pancreatic islet tissue in humans: Autografts and allografts
9. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
10. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: Graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft
11. Problems of islet isolation from the human and porcine pancreas for islet transplantation into men
12. Human islet isolation in 104 consecutive cases. Factors affecting isolation success
13. Factors affecting human islet of Langerhans isolation yields
14. Islet isolation from the pancreas of large mammals and humans: 10 Years of experience
15. Automated method for isolation of human pancreatic islets
16. Collagenase and human islet isolation
17. Improved human islet isolation using a new enzyme blend, liberase
18. Improved method for the isolation and purification of human islets of langerhans using Liberase enzyme blend
19. Endotoxin-mediated activation of cytokine production in human PBMCs by collagenase and Ficoll
20. Endotoxin impairs the engraftment of rat islets transplanted beneath the kidney capsule of C57BL/6-mice
21. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion
22. Isolation of pancreatic islets from dogs. Semiautomated purification on albumin gradients
23. One-hour of hypothermic incubation in Euro-Collins improves islet purification
24. Utilization of anti-acinar cell monoclonal antibodies in the purification of rat and canine islets
25. Gelatin density gradient for isolation of islets of Langerhans
26. A prospective comparison of discontinuous EuroFicoll and EuroDextran gradients for islet purification
27. Isolation, culture and functional evaluation of islets of Langerhans
28. Immunomagnetic isolation of islets from the rat pancreas
29. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe
30. Human islet transplantation network for the treatment of type 1 diabetes: First (1999-2000) data from the Swiss-French GRAGIL consortium
31. Call for moratorium on xenotransplants
32. Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes
33. Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo
34. Impaired expression of transcription factor IUF1 in a pancreatic beta-cell line derived from a patient with persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis)
35. Sulfonylurea receptor 1 and Kir6.2 expression in the novel human insulin-secreting cell line NES2Y
36. 2+
37. Adult human cytokeratin 19-positive cells reexpress insulin promoter factor 1 in vitro: Further evidence for pluripotent pancreatic stem cells in humans
38. Ductal cyst formation in collagen-embedded adult human islet preparations. A means to the reproduction of nesidioblastosis in vitro
39. Human pancreatic ductal cells: Large-scale isolation and expansion
40. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes
41. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice
42. Europe confronts the embryonic stem cell research challenge
43. Autologous islet transplantation to prevent diabetes after pancreatic resection
44. A review of pancreatic islet autotransplantation
45. Human islet transplantation: Lessons from 13 autologous and 13 allogeneic transplantations
46. Pancreas resection and islet autotransplantation for end-stage chronic pancreatitis
47. Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet beta-cells
48. Glucagon receptors on human islet cells contribute to glucose competence of insulin release
49. Characterization of integrin expression in islets isolated from hamster, canine, porcine, and human pancreas
50. Maintenance of beta-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship
51. Glucagon improves insulin secretion from pig islets in vitro
52. Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells
53. Transendothelial neutrophil migration. Role of neutrophil-derived proteases and relationship to transendothelial protein movement
54. Histogenesis and ultrastructure of pancreatic islet graft microvasculature. Evidence for graft revascularization by endothelial cells of host origin
55. Islet transplantation in IDDM patients
56. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management
57. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus
58. Long-term function (6 years) of islet allografts in type 1 diabetes
59. International islet transplant registry
60. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type 1 diabetes mellitus
61. Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients
62. Microencapsulated islets as bioartificial endocrine pancreas
63. Current progress and perspectives in immunoisolated islet transplantation
64. Immunologic tolerance to organ transplants
65. Prope tolerance: A step in the search for tolerance in the clinic
66. Mixed chimerism and transplantation tolerance
67. The immune tolerance network: The "Holy Grail" comes to the clinic
68. Knowledge about transplantation tolerance gained in primates
69. Xenotransplantation of microencapsulated pancreatic islets contained in a vascular prosthesis: Preliminary results
70. Experimental pancreatic islet cell xenotransplantation
71. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane
72. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression
73. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?
74. Transplantation of islets using microencapsulation: Studies in diabetic rodents and dogs
75. Kinetics of intraperitoneally infused insulin in rats. Functional implications for the bioartificial pancreas
76. Cytotoxicity of peritoneal murine macrophages against encapsulated pancreatic rat islets: In vivo and in vitro studies
77. Studies on smaller (approximately 315 microM) microcapsules: IV. Feasibility and safety of intrahepatic implantations of small alginate poly-L-lysine microcapsules